Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals has announced the FDA approval of an additional manufacturer of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis.
Subscribe to our email newsletter
It is prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.
Oxsoralen-Ultra, in combination with a special type of phototherapy called PUVA (Psoralen plus UVA light) therapy, has been shown to improve severe, recalcitrant, disabling psoriasis, the company said.
Valeant Dermatology senior vice president and general manager David Mullarkey said the approval enables them to ensure a steady supply of Oxsoralen-Ultra.